AMA Urges FDA to Adopt Botanical Drug Standards Before Deadline

AMA presses FDA on botanical drug standards

The American Medical Association urged the FDA to apply botanical drug standards before a comment deadline, according to a Cannabis Aficionado report dated Nov. 2, 2026.

That headline is the only detail CannIntel could verify at publication. The docket number, the exact deadline and the text of the AMA submission weren't available, so this story doesn't characterize the group's specific requests. We'll update once the filing posts.

The framework itself is well established. The FDA's botanical drug development guidance, finalized in December 2016, lets sponsors seek approval for complex plant-derived mixtures rather than single synthesized molecules. The agency approved Epidiolex, a plant-derived CBD solution, in June 2018, and it remains the best-known cannabis product to clear that bar.

Why would a physician group care? Medical associations have long argued that if a cannabis product makes therapeutic claims, it should meet drug-grade evidence standards. That position is predictable. What's less clear is how far the AMA wants the FDA to reach into the products already sold as hemp.

Why botanical standards collide with hemp chemistry

A botanical drug pathway demands chemical characterization and batch consistency that most hemp-derived products can't currently show.

Start with THCA. The raw flower's acidic cannabinoid converts to delta-9 THC through decarboxylation, which happens when the plant is heated, whether in a lighter flame or a vape cartridge. The conversion isn't one-to-one. Because THCA has a higher molecular weight, the standard total THC calculation multiplies THCA by roughly 0.877 and adds it to delta-9 THC.

That arithmetic is the center of the hemp loophole fight. The 2018 Farm Bill defined hemp by a 0.3% delta-9 THC limit on a dry-weight basis, which let high-THCA flower test as legal hemp before heating. Total-THC testing closes that gap. Delta-8 THC and similar products sit in a related gray zone, since they're typically made by acid-catalyzed isomerization of CBD, a process that can leave residual reagents and byproducts.

A botanical drug application would force sponsors to document all of that. Composition, identity, potency, contaminants and stability all need to hold from batch to batch. A standard built around reproducibility is a hard fit for a market built around variability.

Not impossible, though. Epidiolex shows the route exists. But it took clinical trials and years of review, plus a purified, tightly specified product. None of that describes a typical gas-station gummy.

What operators should watch next

Hemp and THCA brands face overlapping pressure from FDA drug-pathway arguments and a tightening federal definition of hemp.

Congress rewrote the federal hemp definition in its November 2025 spending law, moving toward a total-THC cap and a limit of 0.4 milligrams per container for finished products. That change is slated to take effect in November 2026, according to the enacted text. Any FDA comment record that leans toward drug-style oversight lands on top of that shift.

The two tracks aren't the same. One is a statutory definition of what counts as hemp. The other is a regulatory question about which products need FDA approval to make health claims or be sold at all. Operators should treat them as separate risks that can compound.

A third variable comes from the DEA, since its scheduling posture on marijuana-derived material affects what any drug sponsor can legally research or manufacture. For full background on this story, see the CannIntel topic hub on FDA botanical drug standards for cannabis.

Practical moves are straightforward. Brands selling THCA flower should be testing for total THC now, not just delta-9. Anyone making health-related statements on CBD or minor cannabinoid labels should assume the FDA's attention is rising, not falling.

The next signal is the docket itself. Once the AMA's submission posts, we'll see whether it targets only drug-claim products or reaches adult-use and hemp-derived intoxicants too. It's unsettled, and readers should expect enforcement to vary by state and by agency.